SLXN Silexion Therapeutics Corp
Financings ·
Silexion's S-3 registers resale of up to 8,813,531 ordinary shares by selling shareholders from an August warrant inducement, a converted sponsor note and stock paid to LifeSci Advisors. The filing also discloses a June 2026 complaint from the sponsor, which seeks repayment of $3.433 million.
Silexion shareholders approved a 500,000,000-share increase in authorized capital and a reverse split. The board chose 1-for-24 from a range of 1-for-15 to 1-for-25. Holders of about 18.6% of shares attended the reconvened meeting, which the articles treat as a quorum.
The company says it needs both measures to protect its Nasdaq listing, with 14,473,292 shares already outstanding against 15,900,000 authorized. Shareholders rejected smaller versions in September.
Holders exercising 3,216,928 existing warrants receive 6,433,856 new warrants that cannot be used until shareholders approve more authorized shares.
A Nasdaq hearings panel is already weighing a delisting over low shareholders' equity. The closing bid price has been below $1.00 for 30 consecutive business days.
Management said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18.
The best-efforts deal closed August 13, 2026. Silexion also converted $750,001 of debt owed to its former SPAC sponsor into shares at the offering price.
Defendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note.
Silexion's 1-for-10 reverse share split took effect after the close of trading on May 28, 2026, and the company's warrants were repriced ten-fold with it. By autumn the company was asking shareholders for another split.
Nasdaq's September 23, 2025 letter confirmed that Silexion meets its $2.5 million shareholders' equity rule and its $1.00 bid-price rule. The company is now under a mandatory panel monitor until September 23, 2026, and one more equity failure in that period would lead to a delisting determination.
Silexion priced a $6.0 million public offering at $4.00 per share and warrants, with H.C. Wainwright as exclusive placement agent. Its prospectus says cash was $3.5 million at June 30, 2025 and carries a going-concern warning.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $7.1 million | $5.8 million |
| Net income (loss) | -$11.9 million | -$16.5 million |
| Cash from operations | -$10.8 million | -$8.4 million |
| Cash and equivalents | $6.0 million | $1.2 million |
Our latest story on this, dated Oct 26, 2026: "Silexion shareholders back a 1-for-24 reverse split and more authorized shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Silexion adds bid-price deficiency to pending Nasdaq panel review". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Silexion had $2.2 million in cash at June 30 and flags going-concern doubt". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Silexion had $2.2 million in cash at June 30 and flags going-concern doubt". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Silexion adds bid-price deficiency to pending Nasdaq panel review". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 22, 2026: "Former SPAC sponsor sues Silexion in Tel Aviv over note conversions". The story links the filing or release it is based on. Read the story.
Silexion Therapeutics Corp trades under the ticker SLXN on NASDAQ.
Silexion Therapeutics Corp is listed on NASDAQ.
The SEC Central Index Key (CIK) for Silexion Therapeutics Corp is 2022416. Its filings are on SEC EDGAR.
5,560,256 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Silexion Therapeutics Corp under Israel.
Our directory classifies Silexion Therapeutics Corp as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Silexion Therapeutics Corp is KYG1281K1489.
aibio.space lists Silexion Therapeutics Corp among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Silexion signed an induced Series E warrant-exercise agreement with new Series F and G warrants. Source
Nasdaq added a bid-price deficiency to the panel review. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
The company appeared before a Nasdaq panel; no final favorable ruling is verified. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Nasdaq issued a new equity-deficiency delisting determination; the company planned an appeal. Source
The second-quarter report retained substantial doubt and a funding estimate through the fourth quarter. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Silexion consummated the August public offering. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Amnon Peled left the board for personal reasons; Avner Lushi filled the audit-committee vacancy. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
The company filed a Form S-3 registration statement; filing alone is not a cash receipt. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
The one-for-ten reverse split became effective after market close; adjusted trading began on 2026-05-29. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
The company completed the May induced warrant exercise, as described in the later voting report. Source
Silexion signed an induced warrant-exercise agreement with replacement Series C and D warrants. Source
The periodic filing included going-concern substantial-doubt language; this event does not carry it forward as current. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Cash and equivalents were $2.229 million at 2026-06-30, with another $91,000 classified as restricted cash. These are dated balances, not current cash. Source
Management projected funding through the fourth quarter of 2026 under its current business plan. This forecast does not remove the substantial-doubt warning. Source
Yes. An equity deficiency and a later bid-price deficiency were before the hearing panel; the opened materials do not establish a final favorable decision. Source
No completed transfer or final removal was verified. The September notice said the ordinary shares would continue trading on the Nasdaq Capital Market at that time. Source
The company adjourned its extraordinary meeting to 2026-10-26 without conducting business. The two proposals, a share capital increase and a reverse split, had not been voted on at that point. Source
No. The meeting rejected both proposals, including the proposed one-for-fifteen split. Source
Yes. A one-for-ten split took effect after market close on 2026-05-28, with adjusted trading on 2026-05-29. Source
The company reported consummation on 2026-08-13 and approximately $2.5 million gross proceeds. Those receipts exclude potential future warrant exercise proceeds. Source
The complaint disputes conversion of sponsor-note debt into shares and seeks alternative monetary relief. Silexion says the claims lack merit; no court finding is asserted. Source
The Form 4 describes Mitchell Shirvan's 2026-03-26 sale of 22,818 shares as a tax sale-to-cover. These are historical units as filed before the later May split. Source
The proxy lists Moringa Sponsor, LP and related persons at 1,954,241 beneficially owned shares and 13.5%, using its stated date and definitions. The sponsor disputes some converted-share ownership. Source
Kesselman & Kesselman signed the audit report and states it has served since 2023. No subsequent auditor change was verified. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio